1. Home
  2. ZURA

as of 05-22-2026 3:32pm EST

$4.37
$0.08
-1.69%
Stocks Health Care Biotechnology: Biological Products (No Diagnostic Substances) Nasdaq

Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.

Founded: 2022 Country:
United States
United States
Employees: 40 City: LA JOLLA
Market Cap: 455.4M IPO Year: N/A
Target Price: $13.00 AVG Volume (30 days): 627.8K
Analyst Decision: Buy Number of Analysts: 6
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: N/A EPS Growth: N/A
52 Week Low/High: $0.99 - $7.25 Next Earning Date: 05-14-2026
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A
P/E Ratio: N/A Index: N/A
Free Cash Flow: N/A FCF Growth: N/A

AI-Powered ZURA Daily Prediction

Machine learning model trained on 25+ technical indicators

Updated 3 days ago

AI Recommendation

hold
Model Accuracy: 67.44%
67.44%
Confidence

Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.

Share on Social Networks: